Piramal Enterprises Limited Patent applications |
Patent application number | Title | Published |
20160031867 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT - The present invention provides a process for the preparation of 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one (Aprepitant) comprising condensation of 2-(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(S)-(4-fluorophenyl)morpholine hydrochloride salt with 2-(2-chloro-1-iminoethyl)hydrazinecarboxylic acid methyl ester to obtain the reaction mixture containing 2-[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl]hydrazinecarboxylic acid methyl ester, which is in-situ cyclized in the presence of dimethylsulfoxide and a polar protic solvent at a low temperature to yield aprepitant having purity ≧99.5%. | 02-04-2016 |
20150265651 | Herbal Composition for the Prevention and Treatment of TNF-ALPHA Mediated Diseases - The present invention relates to a herbal composition for use in the prevention or treatment of a disease mediated by TNF-α. The present invention also provides a method for the preparation of the herbal composition and methods for using such herbal composition. | 09-24-2015 |
20150252001 | PROCESS FOR PREPARATION OF PERINDOPRIL INTERMEDIATE - The present invention relates to an improved process for the preparation Of (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]3-S-oxopropyl]octahydro-1H-indole-2-carboxylic acid benzyl ester (the compound of formula II) comprising reacting (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid phenylmethyl ester | 09-10-2015 |
20150232458 | PROCESS FOR PREPARATION OF TRIGLYCIDYL ISOCYANURATE (TGIC) - The present invention relates to an improved process for the preparation of 1,3,5-triazine-2,4,6(1H,3H,5H)-trione (“Triglycidylisocyanurate (TGIC) or the compound of formula I”) comprising reacting cyanuric acid (the compound of formula III) with 3 to 7 molar equivalents of epichlorohydrin in an autoclave at a temperature of 80-100° C. for 1 hour to give the mixture of intermediates A, B and C and reacting intermediates A, B and C with an alkali to obtain the compound of formula I. | 08-20-2015 |
20150080312 | HEXADEPSIPEPTIDE ANALOGUES AS ANTICANCER COMPOUNDS - This invention relates to an isolated, compound of Formula (1) | 03-19-2015 |
20150072969 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS - The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) | 03-12-2015 |
20150050373 | HERBAL COMPOSITION FOR THE TREATMENT OF METABOLIC DISORDERS - The present invention relates to an herbal composition comprising a therapeutically effective amount of the extract of a plant belonging to | 02-19-2015 |
20150047978 | BIOSENSOR HAVING NANOSTRUCTURED ELECTRODES - The present invention provides a substrate for a microfluidic device comprising a polymeric base plate, at least one sensor formed over the polymeric base plate for detecting at least one target analyte from a sample, the sensor comprising at least one reference electrode and at least one working electrode, wherein a plurality of nanostructures deposited over the working electrode for increasing the surface area of the working electrode, and at least one recognition element bound to or deposited over the nanostructures. The microfluidic device of the present invention is a point-of-care, self calibrated, self contained hand-held device for rapid screening and diagnosis of various disease markers. | 02-19-2015 |
20150011619 | METHOD OF TREATMENT FOR ACNE AND AN ANTI-ACNE FORMULATION - The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; | 01-08-2015 |
20140348950 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) | 11-27-2014 |
20140348919 | ANTIBIOTIC COMPOUNDS - This invention relates to novel purified compounds of Formula I. The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula I and pharmaceutically acceptable salts and derivatives. The present invention further relates to processes for the production of the novel antibacterial compounds by fermentation of the microorganism belonging to | 11-27-2014 |
20140296520 | PROCESS FOR THE PREPARATION OF VALACYCLOVIR HYDROCHLORIDE - The present invention provides a process for the preparation of 2-[(2-amino-1,6-dihydro-6-oxo-9H-yl)]ethyl L-valine ester hydrochloride (valacyclovir hydrochloride) of formula I comprising deprotection of N-[(benzyloxy)carbonyl]-L-valine-2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, of formula II using 5% palladium on carbon as a catalyst and mineral acid in the presence of water, avoiding use of organic solvents under hydrogen pressure to yield valacyclovir hydrochloride having yield of ≧90% and purity of ≧99.5%, pharmaceutically acceptable grade. The valacyclovir hydrochloride obtained using the process of the present invention is valacyclovir hydrochloride polymorphic Form I. | 10-02-2014 |
20140142159 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) | 05-22-2014 |
20140128613 | A PROCESS FOR PREPARATION OF INTERMEDIATES OF DONEPEZIL HYDROCHLORIDE - The present invention provides a process for the preparation of key intermediate for the synthesis 5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1-indanone hydrochloride (donepezil hydrochloride). The present invention particularly provides a process for the preparation of 5,6-dimethoxy-2-(4-pyridylmethylene)-1-indanone comprising condensation of 5,6-dimethoxy-1-indanone with 4-pyridinecarboxaldehyde using an alkali metal hydroxide as a mild base in the presence of demineralized water as a solvent at a temperature in the range of 15° C. to 45° C. to yield 5,6-dimethoxy-2-(4-pyridylmethylene)-1-indanone, which is subsequently benzylated using benzyl bromide in the presence of solvent at a reflux temperature to yield 1-benzyl-4-[(5,6-dimethoxy-1-indanone-2-yl)methylene]pyridinium bromide. | 05-08-2014 |
20140112918 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); | 04-24-2014 |
20140046059 | PROCESS FOR THE PREPARATION OF MORPHOLINO SULFONYL INDOLE DERIVATIVES - The present invention relates to a process for the preparation of the compounds of formula (I) which are morpholino sulphonyl indole derivatives. The compounds of formula (I) are capable of inhibiting, modulating or regulating Insulin-Like-Growth Factor I Receptors or Insulin Receptors. The present invention also relates to the processes for preparation of the pharmaceutically acceptable salts of the compounds of formula (I). | 02-13-2014 |
20140045847 | CRYSTALLINE FORM OF A SALT OF A MORPHOLINO SULFONYL INDOLE DERIVATIVE AND A PROCESS FOR ITS PREPARATION - The present invention relates to a crystalline form of a pharmaceutically acceptable salt of a morpholino sulphonyl indole derivative, that is capable of inhibiting, modulating and/or regulating Insulin-Like-Growth Factor I Receptor and Insulin Receptor. The present invention also relates to a process for the preparation of the crystalline form of said compound. Formula (I): | 02-13-2014 |
20140045832 | Insulin-Like Growth Factor-1 Receptor Inhibitors - The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating Insulin-Like-Growth Factor I Receptor and Insulin Receptor. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds. | 02-13-2014 |
20130323341 | ANTIVIRAL COMPOSITIION - The present invention relates to a composition comprising extract of the plant | 12-05-2013 |
20130310374 | Substituted Imidazoquinoline Derivatives - The present invention relates to substituted imidazo[4,5-c]quinoline derivatives of formula (I), wherein R | 11-21-2013 |
20130237582 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR - The present invention relates to a pharmaceutical combination comprising paclitaxel, or its pharmaceutically acceptable salt; and at least one cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof, for use in the treatment of triple negative breast cancer (TNBC). The present invention relates to a method for the treatment of breast cancer, particularly triple negative breast cancer, by administration to a patient in need thereof, a therapeutically effective amount of a pharmaceutical combination comprising a cytotoxic antineoplastic agent, paclitaxel, and at least one cyclin dependent kinase (CDK) inhibitor; wherein said combination on administration exhibits synergistic effects. | 09-12-2013 |
20130203815 | CYTOKINE INHIBITORS - The present invention provides compounds represented by general formula (I): | 08-08-2013 |
20130158075 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS - The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. | 06-20-2013 |
20130130992 | DIPEPTIDE DERIVATIVE FOR THE TREATMENT OF CANCER - This invention relates to purified compound of formula (1). The invention includes all isomeric forms and all tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts thereof. The present invention further relates to processes for the production of the compound of formula (1) by fermentation of the fungal strain of sterile mycelium (PM0509732/MTCC5544) and to pharmaceutical compositions containing the compound as active ingredient and its use in medicines for treatment of cancer. | 05-23-2013 |
20130125879 | MICROPARTICLE FORMULATION FOR PULMONARY DRUG DELIVERY OF ANTI INFECTIVE MOLECULE FOR TREATMENT OF INFECTIOUS DISEASES - The present invention relates to a biodegradable, inhalable microparticle formulation comprising a compound of formula I obtained by fermentation of a microorganism of the | 05-23-2013 |
20130116248 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R | 05-09-2013 |
20110288899 | CONTROL SYSTEM FOR A WATER DISTRIBUTION SYSTEM - A control system for remotely controlling the operation of a water distribution system is disclosed. The control system comprises a communication interface to enable communication between the control system and the water distribution system such that communication includes receiving from the water distribution system payment for dispensing of water, data on the working of its various components and data on the quality of the water dispensed by it. The control system further comprises a control processor configured to analyse data received from the water distribution system to determine if the quality of the water at the water distribution system satisfies a predetermined quality standard and to determine if the components of the water distribution system are functioning within a predetermined range. The control processor is further configured to issue component parameter adjustment instructions to modify the working of the water distribution system or instructions to stop dispensing of water if the quality standard is not satisfied or the components of the water distribution system are not functioning within the predetermined range. | 11-24-2011 |
20110284433 | WATER DISTRIBUTION SYSTEM - A water distribution system configured for control by a remote control system is disclosed comprising of a water filtration unit for filtering water and a water storage unit for storing the filtered water and including a water dispenser. A control unit is provided that is configured to control the operation of the water filtration unit and includes a sensor system to measure the quality and the quantity of the water filtered, and to monitor the functioning of one or more components of the water filtration unit. A point of sale device is also provided comprising of a service management device mounted on the water dispenser and is configured to control the operation of the water dispenser and a user interface to receive user inputs and is configured to process user payments for the dispensing of water at the remote control system. The system includes a communication gateway enabling communication between the water distribution system and the remote control system such that the water distribution system is configured to transmit data obtained from the sensor system and the user interface to the remote control system. The water distribution system is further configured to receive instructions for the operation of the water filtration unit from the remote control system and to receive instructions for dispensing of water on successful processing of user payment. | 11-24-2011 |